Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-12-02Clinical Trial Update: Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery [Phase 4]
Phase 4 trial update evaluating long-acting naltrexone for sustained abstinence and recovery in opioid-use disorder.
-
CLINICAL_TRIALS trial_result · 2022-12-02Clinical Trial Update: Peer-Delivered Behavioral Activation for Methadone Adherence - Pilot Phase [NA]
Pilot phase trial evaluating peer-delivered behavioral activation to support methadone adherence; study completed with results posted.
-
FDA approval · 2022-11-16FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical's supplemental application for a generic buprenorphine and naloxone product. This approval expands the a…
-
CLINICAL_TRIALS trial_result · 2022-10-27Clinical Trial Update: Pregabalin Versus Gabapentin Opioid Sparing Effect in Discectomy [Phase 3]
Phase 3 clinical trial comparing pregabalin versus gabapentin for opioid-sparing effects in discectomy, status and results not reported.
-
CLINICAL_TRIALS trial_result · 2022-10-26Clinical Trial Update: Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder [Phase 4]
A Phase 4 trial comparing monthly versus daily buprenorphine formulations for treatment of moderate to severe opioid use disorder is ongoing…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2022-10-07Clinical Trial Update: Usability Testing for the Reward-based Technology to Improve OUD Treatment [NA]
A completed usability study evaluating a reward-based technology intended to support treatment for opioid use disorder and contingency manag…
-
CLINICAL_TRIALS trial_result · 2022-10-06Clinical Trial Update: Medication Development for Opioid and Alcohol Abuse [Phase 2]
Phase 2 clinical trial results for a medication targeting opioid-use disorder and alcohol use disorder have been completed, with results pos…
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: INDV-2000 First in Human [Phase 1]
INDV-2000 from Indivior completed its first-in-human Phase 1 trial for opioid use disorder. Results from the study have been posted.
-
CLINICAL_TRIALS trial_result · 2022-09-14Clinical Trial Update: Optimization and Multi-Site Feasibility of Yoga for Chronic Pain in People in YOGAMAT-II - Phase I [NA]
A completed Phase I trial assessing optimization and multi-site feasibility of yoga for chronic pain in people with opioid use issues.
-
CLINICAL_TRIALS trial_result · 2022-09-10Clinical Trial Update: SMART Effectiveness Trial [NA]
The SMART Effectiveness Trial evaluating treatment for opioid use disorder has completed and posted results in September 2022.
-
CLINICAL_TRIALS trial_result · 2022-09-02Clinical Trial Update: Primary Care Intervention to Reduce Prescription Opioid Overdoses [NA]
A completed clinical trial evaluating a primary care intervention intended to reduce prescription opioid overdoses; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-08-24Clinical Trial Update: Medication Maintenance Therapy in Community Pharmacy Settings [Phase 2, Phase 3]
A multi-phase trial update evaluating medication maintenance therapy for opioid-use disorder in community pharmacy settings (Phase 2 and Pha…
-
FDA approval · 2022-08-23FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)
The FDA approved a supplemental application for SUBLOCADE (buprenorphine extended-release) from Indivior Inc., updating the product's labeli…
-
CLINICAL_TRIALS trial_result · 2022-08-19Clinical Trial Update: Galantamine and CBT4CBT Pilot to Prevent Relapse. [EARLY_Phase 1]
Early-phase trial evaluating galantamine in combination with CBT4CBT to prevent relapse in methadone or buprenorphine detoxification patient…
-
CLINICAL_TRIALS trial_result · 2022-08-17Clinical Trial Update: Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence [Phase 3]
Phase 3 trial update on neuroimaging predictors of relapse during treatment for opioid addiction; results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-08-16Clinical Trial Update: Application of Economics & Social Psychology to Improve Opioid Prescribing Safety (AESOPS): R21 Pilot Phase [NA]
A completed pilot study (R21) investigating economics and social psychology approaches to improve opioid prescribing safety; results posted …
-
CLINICAL_TRIALS trial_result · 2022-08-01Clinical Trial Update: The O'Neil Long Acting Naltrexone Implant (OLANI) Pharmacokinetic (PK)/Safety Study in Healthy Volunteers [Phase 1]
Phase 1 pharmacokinetic and safety study evaluating the OLANI long-acting naltrexone implant in healthy volunteers to characterize pharmacok…
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: Appropriate Opioid Quantities for Acute Pain - Pharmacist Study [Phase 4]
A Phase 4 clinical trial evaluating appropriate opioid quantities for acute pain conducted by the Centre for Addiction and Mental Health has…
-
CLINICAL_TRIALS trial_result · 2022-06-28Clinical Trial Update: Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD [NA]
Clinical trial assessing ED-initiated buprenorphine for opioid use disorder using clinical decision support; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-06-21Clinical Trial Update: A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders [Phase 3]
Phase 3 trial evaluating strategies to improve success of treatment discontinuation in buprenorphine responders for opioid-use disorder; stu…
-
FDA approval · 2022-06-17FDA Approved: SUBOXONE — Supplemental Application (INDIVIOR INC.)
The FDA approved a supplemental application for SUBOXONE (buprenorphine hydrochloride/naloxone hydrochloride) submitted by Indivior Inc.
-
FDA approval · 2022-06-17FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Amneal's buprenorphine HCl and naloxone HCl tablets, enabling a generic option for treating opio…
-
FDA approval · 2022-06-17FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for buprenorphine and naloxone by Actavis Pharma, Inc. This approval updates the product's labeling …
-
FDA approval · 2022-06-17FDA Approved: BUPRENORPHINE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for buprenorphine submitted by Actavis Pharma, Inc.
-
FDA approval · 2022-06-17FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
The FDA approved a supplemental ANDA for a buprenorphine/naloxone product (buprenorphine hydrochloride and naloxone hydrochloride) from PAI …